In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of tisotumab vedotin (TTV) for the treatment of solid tumors. The main outcome will be the response rate to treatment. This trial will take place in the United States, France, and Italy. The details Colorectal cancer (CRC) is caused by excessive cell growth...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of tisotumab vedotin (TTV) for the treatment of solid tumors. The main outcome will be the response rate to treatment. This trial will take place in the United States, France, and Italy. The details Non-small cell lung cancer (NSCLC) is caused by excessive cell growth in...
Read MoreIn a nutshell This trial is investigating the effects of AVD [doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC)] with brentuximab vedotin (Adcetris) induction chemotherapy, plus nivolumab (Opdivo) for Hodgkin lymphoma (HL). The main outcome to be measured is survival without cancer worsening 3 years after treatment. The details...
Read More
In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...
Read MoreIn a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for high-risk...
Read More
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for...
Read More
In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read MoreIn a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...
Read More
In a nutshell This phase 3 trial is investigating the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for mantle cell lymphoma (MCL). The main outcomes to be measured will be survival without cancer growing or spreading and side effects of treatment. The details Mantle cell lymphoma (MCL) is an aggressive type of...
Read More
